GlassScriptPhysician profile
Russell W Smith
NPI 1902497142
$4,128.32
in general payments reported to CMS, 2019-2025
50 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $227 · 2024: $1,762 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,128.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $397.10 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $309.65 | 2023-2025 | Enhertu, Calquence, Lynparza |
| Daiichi Sankyo INC. | $278.17 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $248.04 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $245.38 | 2024-2025 | Libtayo |
| Genentech USA, INC. | $219.89 | 2023-2025 | Polivy, Phesgo, Itovebi |
| Genzyme Corporation | $183.39 | 2024-2025 | |
| Janssen Biotech, INC. | $177.54 | 2024-2025 | Darzalex, Erleada, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $148.51 | 2024-2025 | Iclusig, Ninlaro, Alunbrig |
| Pfizer INC. | $148.10 | 2024-2025 | |
| Abbvie INC. | $123.99 | 2024-2025 | |
| Gilead Sciences, INC. | $115.44 | 2023-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $100.59 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $95.28 | 2024-2025 | |
| Lilly USA, LLC | $95.13 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.